Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relicpixant in subacute cough
NCT06920836Phase 2Completed
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd.
- Start
- Jun 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of relicpixant (3 arms), sponsored by Wuhan Createrna Science and Technology Co., Ltd. Primary endpoint: Geometric Mean Ratio (GMR) of mean coughs per hour within 24 hours on Day 10 versus baseline. Started Jun 2023; status: completed.
02
Drugs
relicpixant
Beyond the preview
Go deeper on NCT06920836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06920836.